Group 1: Moderna's Earnings Outlook - Moderna is expected to report a year-over-year decline in earnings, with a projected loss of $2.65 per share, reflecting a change of -581.8% [3][12] - Revenues for the upcoming quarter are anticipated to be $955.23 million, down 66% from the same quarter last year [3] - The earnings report is scheduled for release on February 14, 2025, and could influence stock movement based on whether results exceed or fall short of expectations [2][12] Group 2: Earnings Estimate Revisions - The consensus EPS estimate for Moderna has been revised 7.2% higher in the last 30 days, indicating a more optimistic outlook from analysts [4] - The Most Accurate Estimate for Moderna is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +3.26%, suggesting a likelihood of beating the consensus EPS estimate [10][11] Group 3: Historical Performance and Predictive Indicators - Moderna has a history of beating consensus EPS estimates, having done so in the last four quarters [13] - The predictive power of the Earnings ESP is significant for positive readings, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [8] - Despite a positive earnings outlook, other factors may also influence stock performance, making it essential to consider broader market conditions [14][16] Group 4: Industry Comparison - In the Zacks Medical - Biomedical and Genetics industry, Alnylam Pharmaceuticals is expected to post a loss of $0.21 per share, indicating a year-over-year change of +80.9% [17] - Alnylam's revenue is projected to be $570.11 million, up 29.7% from the previous year, but it has an Earnings ESP of -192.68%, complicating predictions for beating the consensus EPS estimate [18]

We expect Moderna (MRNA) to surpass expectations when it reports fourth-quarter and full-year 2024 earnings on Feb. 14, before the opening bell. In the last reported quarter, MRNA’s earnings beat estimates by 101.59%.The Zacks Consensus Estimate for sales and earnings is pegged at $955.23 million and at a loss of $2.65 per share, respectively. Both metrics indicate a significant decline from the year-ago levels.See the Zacks Earnings Calendar to stay ahead of market-making news.Factors Shaping MRNA’s Upcomi ...

Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm lowered its rating on MRNA to "neutral" from "buy," and nearly halved its price target from $99 to $51, citing ongoing vaccine revenue challenges.If these pre-market losses hold, Moderna stock could erase part of its 8.1% year-to-date lead and deepen its 57.1% year-over-year loss. The equity may also slip below a critical technical level -- its 20-day moving average -- which could pressure ...

Industry Overview - The U.S. government, under President Trump, announced a $500 billion investment in AI infrastructure, which is expected to significantly impact the standard of living in the U.S. and globally [1] - The Smart Healthcare Market is projected to grow by $125.7 billion by 2028, indicating a strong trend towards AI adoption in healthcare [1] Company Developments - Avant Technologies, Inc. is collaborating with Ainnova Tech to advance AI-driven healthcare innovations, specifically focusing on early disease detection [3][4] - Ainnova is preparing to engage with the U.S. FDA for its Vision AI platform aimed at detecting diabetic retinopathy, with a pre-submission meeting expected in late March/early April 2025 [6][5] - Avant Technologies has partnered with Roche to launch a pilot program in Costa Rica that utilizes VisionAI for automated retinal image analysis, with plans for broader adoption in North America and Europe [7][8] Investment Highlights - Spotify's founder Daniel Ek's HealthTech startup, Neko Health, recently secured $260 million in financing, valuing the company at approximately $1.8 billion, showcasing investor interest in HealthTech [2] - Moderna's shares surged 14% following the announcement of Project Stargate, which emphasizes AI's role in developing personalized mRNA vaccines [9] - Merck has integrated AI into its drug discovery processes and has launched the AIDDISON™ platform, indicating a trend of pharmaceutical companies leveraging AI for operational efficiency [11] Strategic Partnerships - GE HealthCare Technologies signed a $247 million deal to enhance diagnostic services in the UK, demonstrating the application of AI in improving healthcare delivery [12][13] - Teladoc Health announced a collaboration with Amazon to expand chronic condition management programs, enhancing accessibility for patients [14]

Moderna (MRNA) closed the latest trading day at $41.66, indicating a +0.6% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of 1.46%. Elsewhere, the Dow saw an upswing of 0.65%, while the tech-heavy Nasdaq depreciated by 3.07%.Prior to today's trading, shares of the biotechnology company had gained 3.19% over the past month. This has outpaced the Medical sector's gain of 1.84% and the S&P 500's gain of 1.08% in that time.Market participants will be cl ...

Are you ready for artificial intelligence (AI)-driven mRNA vaccines?Shares of Moderna (MRNA -2.31%) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence.The maker of vaccines, including the mRNA vaccine for COVID-19, is amid a 90% stock price downturn. In fact, the share price is now only right around the same level as it was before the 2020 pandemic. However, this week, the company got good news with a mention of mRNA vaccines at the Project Stargate announcement ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (MRNA -2.31%) as a biotech that'll never recover its former glory -- which it built on the success of its coronavirus vaccine program. But where there are widespread bearish sentiments about a stock, there's also often an opportunity for investors who are willing to focus on the long term and appreciate that things won't always be like they are now.In that vein, let's learn about the three most important things you sh ...

Core Insights - Moderna is developing a vaccine for norovirus, with a large phase three trial currently underway, and results expected as early as late 2024 or 2026 [2][10] - The current winter has seen a significant increase in norovirus cases, with a 36% rise in outbreaks compared to the previous season, and twice as many positive tests reported in January [4][3] - The vaccine candidate targets three genotypes of norovirus, but does not include the genotype responsible for most infections this year [5][6] Company Strategy - The primary goal of the vaccine is not to completely prevent norovirus but to reduce the severity of symptoms and prevent hospital visits [7] - The company aims to vaccinate vulnerable populations, particularly seniors aged 65 and above, who are at higher risk of complications from norovirus [8] - Other target groups include healthcare workers, daycare workers, and individuals on cruise ships, as these populations are frequently exposed to norovirus [9][10] Market Considerations - Investors are skeptical about the commercial viability of the vaccine, contingent on its effectiveness, with a focus on protecting those in nursing homes and cruise passengers [10] - The vaccine is not currently being tested in children, but if successful in adults, further studies in children will be necessary [10]

Tuesday, Moderna Inc MRNA stock is trading higher with a session volume of 8.0 million as per data from Benzinga Pro.On Friday, Moderna announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines.The award was made through the Rapid Response Partnership Vehicle (RRPV) Consortium with funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Administration for Strategic Pre ...

Moderna's Vaccine Development - Moderna received a $590 million grant from the U S Department of Health and Human Services to accelerate the development of mRNA-based pandemic influenza vaccines, including mRNA-1018 [1][5] - The company initiated Phase 1/2 testing of mRNA-1018 in 2023, targeting healthy adults aged 18 and above, with positive preliminary results leading to the launch of a Phase 3 study [2][5] Bird Flu Impact and Market Response - The Centers for Disease Control and Prevention (CDC) reported widespread bird flu in wild birds and outbreaks in poultry and U S dairy cows, with several human cases among dairy and poultry workers [3] - Cal-Maine Foods, the largest U S egg producer, noted rising egg prices due to production limits caused by the bird flu outbreak [4] - Despite a 5% increase in Moderna's stock price, shares remain nearly 65% lower over the past year due to declining COVID-19 vaccine sales [4]